Atlas Trials

MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma

Clinical trial NCT01987505 · COMPLETED

Trial details

NCT number
NCT01987505
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Lymphoma, Non Hodgkin
Start date
2013-11-11
Primary completion
2017-04-11
Enrollment
140

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.